electroCore, Inc. (Nasdaq:ECOR) Hits 52 Week Low

electroCore, Inc. (Nasdaq:ECOR)

May 15th, 2019

With markets going up electroCore, Inc. fell ($1.58) Wednesday, down 29.64%, closing at $3.75. As well as the drop in value, electroCore, Inc. hit a new 52 week low of $3.72, breaking the previous low of $4.68 from earlier this February. electroCore, Inc. bounced 36.29% between low and high. Despite the drop in value, trading volumes were solid at 609.00% of normal which can indicate investor opportunities. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be 0.00.

ECOR was outperformed by the rest of the Healthcare sector which went up 0.27%.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending up. Communication Services saw the biggest increase of the day (2.11%), while Financials saw the biggest drop (-0.48%). Information Technology has seen the biggest year-to-date gain at 21.11%.

Communication Services saw the biggest turnaround from its 5-day performance of -0.19%, as it went up 2.11%. Utilities saw a turn around from its 5-day performance of 1.74% trading down -0.13%.

Sector Breakdown

  • Communication Services went up with a 2.11% change.
  • Information Technology went up with a 0.98% change.
  • Consumer Staples went up with a 0.80% change.
  • Consumer Discretionary went up with a 0.78% change.
  • Real Estate went up with a 0.64% change.
  • Energy went up with a 0.46% change.
  • Healthcare went up with a 0.27% change.
  • Industrials went up with a 0.12% change.
  • Utilities went down with a -0.13% change.
  • Materials went down with a -0.24% change.
  • Financials went down with a -0.48% change.

electroCore, Inc. Info

electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that electroCore, Inc.’s score is 0.00) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

ECOR daily update
ECOR daily update

Via UnSplash

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.